GMR Infrastructure renamed as GMR Airports Infrastructure

Earlier this month, the Board of GMR Infrastructure also approved raising funds of up to Rs 6,000 crore via foreign currency convertible bonds and/or any other security.

Moneycontrol News

September 16, 2022 / 15:15 IST

Representational image

live

bselive
nselive

Volume

Todays L/H

GMR Infrastructure has been renamed as GMR Airports Infrastructure with effect from September 15, in order to reflect the fact that the company is now primarily a holding company for the GMR Group's airport assets, according to a stock exchange notification on September 16.

The GMR Group had in August 2020 announced its plans to restructure its various business verticals, spin-off and list its airports business separately.

The scheme of amalgamation, which involved the demerger of GMR Power Infra from GMR Infrastructure, was completed in December 2021.

GMR group’s airport portfolio has around 172 million passenger capacity in operation and under development, comprising India's busiest Indira Gandhi International Airport in New Delhi and Hyderabad’s Rajiv Gandhi International Airport.

The GMR group also operates Mactan Cebu International Airport in partnership with Megawide in the Philippines while greenfield projects under development includes an airport at Mopa in Goa and another airport at Heraklion, Crete, Greece in partnership with GEK Terna.

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show